**Supplementary Table 2.** Results of testing with the new eye tracker (SVOP v3) compared to SVOP v2 and SAP.

<table>
<thead>
<tr>
<th>Glaucoma (G) or healthy subject (H)</th>
<th>Visual field defect grading</th>
<th>SVOP v2</th>
<th>SVOP v3</th>
<th>SAP</th>
</tr>
</thead>
<tbody>
<tr>
<td>G</td>
<td></td>
<td>3</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>G</td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>G</td>
<td>Incomplete</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>G</td>
<td>Incomplete</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>G</td>
<td>Incomplete</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>G</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>G</td>
<td></td>
<td>2</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>G</td>
<td>Incomplete</td>
<td>3</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>H</td>
<td>Incomplete</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>Incomplete</td>
<td>0</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>